Type I Interferons in Systemic Autoimmune Diseases: Distinguishing Between Afferent and Efferent Functions for Precision Medicine and Individualized Treatment

Autor: Jean-Michel Dayer, François Chasset, Carlo Chizzolini

Publikováno v: Frontiers in Pharmacology
Frontiers in Pharmacology, Frontiers, 2021, 12, pp.633821. ⟨10.3389/fphar.2021.633821⟩
Frontiers in Pharmacology, Vol 12 (2021)

International audience; A sustained increase in type I interferon (IFN-I) may accompany clinical manifestations and disease activity in systemic autoimmune diseases (SADs). Despite the very frequent presence of IFN-I in SADs, clinical manifestations

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79ba0ade324d0cde915f665760bb2501
https://hal.sorbonne-universite.fr/hal-03229661/document

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.